Literature DB >> 1501114

The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism.

E H Ohlstein1, M Gellai, D P Brooks, L Vickery, J Jugus, A Sulpizio, R R Ruffolo, J Weinstock, R M Edwards.   

Abstract

The angiotensin II (AII) receptor antagonist, DuP 753 (10 mg/kg intraduodenal), produced a sustained and long-lasting antihypertensive effect in conscious renin-dependent hypertensive rats. Blood pressures were still reduced markedly 24 to 72 hr after administration of a single dose of DuP 753. However, pressor responses elicited by either angiotensin I or AII were not blocked at these times despite the continued antihypertensive effect of DuP 753. In a model of orthostatic hypotension, DuP 753 and the selective alpha-1 adrenoceptor antagonist prazosin produced a marked orthostatic hypotension response in renin-dependent hypertensive rats as demonstrated by potentiation of the decrease in blood pressure induced by a 90 degrees tilt. The nonpeptide AII receptor antagonist SK&F 108566 (10 mg/kg intraduodenal) did not produce orthostatic hypotension and the angiotensin converting enzyme inhibitor enalapril produced only a slight orthostatic response to tilting. In conscious spontaneously hypertensive rats (SHR), allowed 3 to 4 days to recover from surgery, administration of either enalapril (1 mg/kg i.v.) or SK&F 108566 (10 mg/kg i.v.) did not significantly effect blood pressure. In SHR tested within 24 hr of surgery, enalapril was effective in lowering blood pressure. In contrast, in surgically recovered SHR, DuP 753 (10 mg/kg i.v.) produced an antihypertensive effect that was slow in onset, sustained and extremely long in duration. Blood pressures did not return to predrug levels until 48 hr after administration of DuP 753. Stimulation of the thoracolumbar sympathetic outflow in pithed rats produced frequency-dependent pressor responses that were significantly potentiated by continuous infusion of a subpressor dose of AII.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1501114

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Evidence for a functional cardiac interaction between losartan and angiotensin-(1-7) receptors revealed by orthostatic tilting test in rats.

Authors:  Marina Matos de Moura; Robson Augusto Sousa dos Santos; Marco Antônio Peliky Fontes
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

Review 2.  Control of cardiomyocyte gene expression as drug target.

Authors:  H Rupp; M Benkel; B Maisch
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

3.  Further investigations into the mechanism of the antihypertensive activity of the angiotensin AT1 receptor antagonist, GR138950.

Authors:  A Hilditch; H M Prior; G M Drew
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

4.  Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects.

Authors:  Arash Y Tehrani; Zoe White; Lin Wei Tung; Roy Ru Yi Zhao; Nadia Milad; Michael A Seidman; Elodie Sauge; Marine Theret; Fabio M V Rossi; Mitra Esfandiarei; Casey van Breemen; Pascal Bernatchez
Journal:  Sci Rep       Date:  2022-06-13       Impact factor: 4.996

5.  Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist.

Authors:  A Hilditch; A A Hunt; C J Gardner; D J Twissell; J Polley; A Travers; G M Drew; D Middlemiss; B C Ross; M J Robertson
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

6.  Cardiovascular reactivity after blockade of angiotensin AT1 receptors in the experimental model of tilting test in conscious rats.

Authors:  D Bedette; R A S Santos; M A P Fontes
Journal:  Br J Pharmacol       Date:  2008-01-14       Impact factor: 8.739

7.  In vivo pharmacological characterization of the non-peptide endothelin receptor antagonist SB 209670.

Authors:  S A Douglas; R M Edwards; J D Elliott; E H Ohlstein
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

Review 8.  Angiotensin II during Experimentally Simulated Central Hypovolemia.

Authors:  Theo Walther Jensen; Niels Vidiendal Olsen
Journal:  Front Cardiovasc Med       Date:  2016-03-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.